Prostate Adenocarcinoma Clinical Trial
— NADIROfficial title:
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Verified date | February 2024 |
Source | NRG Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.
Status | Suspended |
Enrollment | 180 |
Est. completion date | December 31, 2028 |
Est. primary completion date | January 30, 2028 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed (within 180 days prior to registration) adenocarcinoma of the prostate at high risk for recurrence as determined by the following criteria, according to American Joint Committee on Cancer (AJCC) 8th edition: - Phase I enrollment - Gleason = 9, PSA = 150 ng/mL, any T-stage - Phase II enrollment - Gleason = 9, PSA = 150 ng/mL, any T-stage - Gleason 8, PSA < 20 ng/mL, and = T2 - Gleason 8, PSA = 20-150 ng/mL, any T-stage - Gleason 7, PSA = 20-150 ng/mL, any T-stage - No distant metastases as evaluated by: - Bone scan 90 days prior to registration - Lymph node assessment by computed tomography (CT) or magnetic resonance (MR) of pelvis or nodal sampling within 90 days prior to registration (Please note: Lymph nodes will be considered negative (N0) if they are < 1.5 cm short axis) - History/physical examination within 90 days prior to registration - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 180 days prior to registration - Pretreatment serum PSA, obtained prior to any androgen suppression therapy and within 180 days of registration - Phase I patients: Prior androgen suppression for prostate cancer is not allowed prior to registration - Phase II patients: Prior androgen suppression for prostate cancer is allowed = 45 days prior to registration - Hemoglobin = 9.0 g/dL (within 90 days prior to registration) - Platelets = 100,000 cells/mm^3 (within 90 days prior to registration) - Absolute neutrophil count (ANC) = 1.5 x 10^9/L (within 90 days prior to registration) - Serum creatinine =1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance >= 30 mL/min estimated using Cockcroft-Gault equation (within 90 days prior to registration) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN (within 90 days prior to registration) - Serum albumin = 3 g/dL (within 90 days prior to registration) - Serum potassium = 3.5 mmol/L (within 90 days prior to registration) - Serum total bilirubin = 1.5 x ULN or direct bilirubin = 1 x ULN (Note: in subjects with Gilberts syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin, and if direct bilirubin is = 1.5 x ULN, subject may be eligible) (within 90 days prior to registration) - Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry Exclusion Criteria: - PSA > 150 ng/mL - Definitive clinical or radiologic evidence of metastatic disease - Pathologically positive lymph nodes or nodes > 1.5 cm short axis on CT or MR imaging - Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason - Any active malignancy within 2 years of study registration that may alter the course of prostate cancer treatment. - Prior systemic therapy for prostate cancer; note that prior therapy for a different cancer is allowable - Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields - Current treatment with first generation anti-androgens (bicalutamide, nilutamide, flutamide). For patients enrolled to phase II, if prior anti-androgens were administered, a washout period of >= 30 days is required prior to enrollment - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Uncontrolled acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition - Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] >=160 mmHg or diastolic BP >= 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment - Prior allergic reaction to the drugs involved in this protocol (including known allergies, hypersensitivity or intolerance to the excipients of niraparib. Please see Niraparib IB for details.) - Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter - Note that patients who are HIV positive are eligible, provided they have a CD4 count >= 200 cells/microliter within 90 days prior to registration. Patients receiving treatment with highly active antiretroviral therapy (HAART) will not be eligible due to concern for radiosensitization - Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be affected by these drugs. - Any history or current diagnosis of Myelodysplasitc Syndromes (MDS)/ Acute Myeloid Leukemia (AML). - Prior or current treatment with PARP inhibitor |
Country | Name | City | State |
---|---|---|---|
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
United States | Summa Health System - Akron Campus | Akron | Ohio |
United States | Alton Memorial Hospital | Alton | Illinois |
United States | Emory Saint Joseph's Hospital | Atlanta | Georgia |
United States | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia |
United States | Grady Health System | Atlanta | Georgia |
United States | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland |
United States | Summa Health System - Barberton Campus | Barberton | Ohio |
United States | McLaren Cancer Institute-Bay City | Bay City | Michigan |
United States | Massachusetts General Hospital Cancer Center | Boston | Massachusetts |
United States | Henry Ford Cancer Institute-Downriver | Brownstown | Michigan |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | AtlantiCare Health Park-Cape May Court House | Cape May Court House | New Jersey |
United States | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati | Ohio |
United States | McLaren Cancer Institute-Clarkston | Clarkston | Michigan |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Henry Ford Macomb Hospital-Clinton Township | Clinton Township | Michigan |
United States | Central Maryland Radiation Oncology in Howard County | Columbia | Maryland |
United States | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Henry Ford Medical Center-Fairlane | Dearborn | Michigan |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | AtlantiCare Surgery Center | Egg Harbor Township | New Jersey |
United States | Weisberg Cancer Treatment Center | Farmington Hills | Michigan |
United States | McLaren Cancer Institute-Flint | Flint | Michigan |
United States | Singh and Arora Hematology Oncology PC | Flint | Michigan |
United States | The New York Hospital Medical Center of Queens | Flushing | New York |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | UM Baltimore Washington Medical Center/Tate Cancer Center | Glen Burnie | Maryland |
United States | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana |
United States | Prisma Health Cancer Institute - Eastside | Greenville | South Carolina |
United States | Prisma Health Cancer Institute - Faris | Greenville | South Carolina |
United States | Saint Francis Cancer Center | Greenville | South Carolina |
United States | Self Regional Healthcare | Greenwood | South Carolina |
United States | Prisma Health Cancer Institute - Greer | Greer | South Carolina |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | University of Kansas Cancer Center | Kansas City | Kansas |
United States | University of Kansas Cancer Center - North | Kansas City | Missouri |
United States | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan |
United States | Mid-Michigan Physicians-Lansing | Lansing | Michigan |
United States | McLaren Cancer Institute-Lapeer Region | Lapeer | Michigan |
United States | University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri |
United States | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania |
United States | Lewistown Hospital | Lewistown | Pennsylvania |
United States | Cedars Sinai Medical Center | Los Angeles | California |
United States | Fremont - Rideout Cancer Center | Marysville | California |
United States | Summa Health Medina Medical Center | Medina | Ohio |
United States | Froedtert Menomonee Falls Hospital | Menomonee Falls | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Zablocki Veterans Administration Medical Center | Milwaukee | Wisconsin |
United States | West Virginia University Healthcare | Morgantown | West Virginia |
United States | McLaren Cancer Institute-Macomb | Mount Clemens | Michigan |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Medical Oncology Hematology Consultants PA | Newark | Delaware |
United States | Rutgers New Jersey Medical School | Newark | New Jersey |
United States | CTCA at Southeastern Regional Medical Center | Newnan | Georgia |
United States | Henry Ford Medical Center-Columbus | Novi | Michigan |
United States | Drexel Town Square Health Center | Oak Creek | Wisconsin |
United States | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | University of Kansas Cancer Center-Overland Park | Overland Park | Kansas |
United States | McLaren Cancer Institute-Northern Michigan | Petoskey | Michigan |
United States | Eastern Regional Medical Center | Philadelphia | Pennsylvania |
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | McLaren-Port Huron | Port Huron | Michigan |
United States | Highland Hospital | Rochester | New York |
United States | University of Rochester | Rochester | New York |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Siteman Cancer Center-South County | Saint Louis | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri |
United States | Prisma Health Cancer Institute - Seneca | Seneca | South Carolina |
United States | Henry Ford Macomb Health Center - Shelby Township | Shelby | Michigan |
United States | Stony Brook University Medical Center | Stony Brook | New York |
United States | Holy Name Hospital | Teaneck | New Jersey |
United States | University of Arizona Cancer Center-North Campus | Tucson | Arizona |
United States | University of Arizona Cancer Center-Orange Grove Campus | Tucson | Arizona |
United States | City of Hope Upland | Upland | California |
United States | Carle Cancer Center | Urbana | Illinois |
United States | George Washington University Medical Center | Washington | District of Columbia |
United States | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin |
United States | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Wisconsin |
United States | Henry Ford West Bloomfield Hospital | West Bloomfield | Michigan |
United States | University of Cincinnati Cancer Center-West Chester | West Chester | Ohio |
United States | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas |
United States | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
NRG Oncology | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exome sequencing of deoxyribonucleic acid (DNA) repair genes and detected alterations | Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. | Up to 3 years | |
Other | Transcription-wide analysis of gene expression | Will be assessed using a high-density Affymetrix oligonucleotide array to profile the transcriptome of tumor samples. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. | Up to 3 years | |
Other | Single nucleotide polymorphisms | Will be analyzed in whole blood samples previously associated with prostate risk. Plasma samples will be assessed for baseline and post-therapy alterations in a targeted gene panel and for reversion mutations in DNA repair genes as early biomarkers of treatment resistance. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. | Up to 3 years | |
Primary | Maintenance of disease-free state | Will be characterized by PSA values sustained below 0.1 ng/ml. A modified intent-to-treat analysis will be conducted. The proportion of patients disease-free at 24 months will be compared in the two treatment arms using a non continuity-corrected chi-square test. As a secondary analysis, a logistic regression model will be fit to adjust for the stratification factors (risk group and type of radiation therapy). | Up to 2 years following the start of antiandrogen therapy | |
Secondary | Overall Survival | Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. | From randomization until death from any cause, assessed up to 3 years | |
Secondary | Prostate cancer-specific survival | Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. | From randomization until death from prostate cancer, assessed up to 3 years | |
Secondary | Pathologic Complete Response (pCR) | Will be assessed among patients undergoing 12-core biopsy. Will be compared using a chi-square test. | At 24 months | |
Secondary | Time to local/regional or distant progression | Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008). | Up to 3 years | |
Secondary | Time to distant metastases | Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008). | From randomization until detection of distant metastatic disease, assessed up to 3 years | |
Secondary | Biochemical Progression-Free Survival | Will be defined as PSA >= 2 ng/ml over the nadir PSA, the presence of local, regional, or distant recurrence, or death from prostate cancer. Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. | Up to 3 years | |
Secondary | Incidence of Adverse Events (Phase II) | Adverse event (AE) rates in the two treatment arms will be summarized by time of occurrence (early versus late), type, grade, and attribution to treatment. For each type of AE, the worst grade occurring during the early treatment period, late treatment period, or entire treatment period will be determined. For each time period, treatment group comparisons will be conducted using chi-square or Fisher exact tests. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03796767 -
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT05735223 -
A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence
|
N/A | |
Recruiting |
NCT04175431 -
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
|
Phase 2 | |
Completed |
NCT05197257 -
68Ga-PSMA-11 PET in Patients With Prostate Cancer
|
Phase 3 | |
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT02254746 -
A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05496959 -
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
|
Phase 2 | |
Completed |
NCT02940262 -
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
|
Phase 3 | |
Recruiting |
NCT04391556 -
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT03503643 -
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
|
||
Recruiting |
NCT05832086 -
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
|
Phase 2 | |
Suspended |
NCT05064111 -
Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
|
||
Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT02600156 -
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
|
N/A | |
Recruiting |
NCT05726292 -
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04423211 -
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
|
Phase 3 | |
Terminated |
NCT03718338 -
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
|
||
Terminated |
NCT02564549 -
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
|
N/A |